Stable formulations for lyophilizing therapeutic particles
View Patent ↗The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.
1. A method of preparing a reconstituted lyophilized pharmaceutical composition suitable for parenteral administration, comprising:
providing a formulation comprising polymeric nanoparticles, wherein the polymeric nanoparticles comprise a therapeutic agent and a polymer selected from the group consisting of poly(lactic) acid-block-poly(ethylene)glycol copolymer and poly(lactic)-co-poly(glycolic) acid-block-poly(ethylene)glycol copolymer;
adding hydroxypropyl β-cyclodextrin and a sugar selected from the group consisting of trehalose and sucrose to the formulation such that the formulation has 7 to 12 weight percent of the hydroxypropyl β-cyclodextrin and 4 to 6 weight percent of the sugar;
lyophilizing the formulation to form a lyophilized formulation; and
reconstituting the lyophilized formulation in an aqueous medium to form the reconstituted lyophilized pharmaceutical composition, wherein the reconstituted lyophilized pharmaceutical composition has a concentration of 10-100 mg/mL of the polymeric nanoparticles.
2. The method of claim 1 , wherein the sugar is trehalose.
3. The method of claim 1 , wherein the sugar is sucrose.
4. The method of claim 1 , wherein the reconstituted lyophilized pharmaceutical composition comprises less than 6000 microparticles of greater than or equal to 10 microns; and less than 600 microparticles of greater than or equal to 25 microns; per sample container having less than or about 100 mL of the composition.
5. The method of claim 1 , wherein the reconstituted lyophilized pharmaceutical composition comprises less than 3000 microparticles having a size greater than or equal to 10 microns; and less than 300 microparticles having a size greater than or equal to 25 microns; per sample container having less than or about 100 mL of the composition.
6. The method of claim 1 , wherein the reconstituted lyophilized pharmaceutical composition has minimal aggregation compared to a reconstituted lyophilized pharmaceutical composition that does not contain a cyclodextrin.
7. The method of claim 1 , wherein the polymer is poly(lactic) acid-block-poly(ethylene)glycol copolymer.
8. The method of claim 7 , wherein the poly(lactic) acid-block-poly(ethylene)glycol copolymer comprises poly(lactic acid) having a number average molecular weight of about 15 to about 20 kDa and poly(ethylene)glycol having a number average molecular weight of about 4 to about 6 kDa.
9. The method of claim 8 , wherein the poly(lactic acid) has a number average molecular weight of about 16 kDa and the poly(ethylene)glycol has a number average molecular weight of about 5 kDa.
10. The method of claim 1 , wherein the polymer is poly(lactic)-co-poly(glycolic) acid-block-poly(ethylene)glycol copolymer.
11. The method of claim 1 , wherein the therapeutic agent is docetaxel.
12. The method of claim 1 , wherein the reconstituted lyophilized pharmaceutical composition comprises about 40-60 mg/mL concentration of polymeric nanoparticles.
13. The method of claim 1 , wherein the polymeric nanoparticles have a diameter of about 60 nm to about 140 nm.
14. A method of preparing a pharmaceutically acceptable aqueous solution, comprising:
providing a formulation comprising polymeric nanoparticles, wherein the polymeric nanoparticles comprise a therapeutic agent and a polymer selected from the group consisting of poly(lactic) acid-block-poly(ethylene)glycol copolymer and poly(lactic)-co-poly(glycolic) acid-block-poly(ethylene)glycol copolymer;
adding hydroxypropyl β-cyclodextrin and sucrose to the formulation such that the formulation has 7 to 12 weight percent of the hydroxypropyl β-cyclodextrin and 4 to 6 weight percent of the sucrose;
lyophilizing the formulation to form a lyophilized formulation; and
reconstituting the lyophilized formulation in an aqueous medium to form the pharmaceutically acceptable aqueous solution, wherein the pharmaceutically acceptable aqueous solution has a concentration of 40-60 mg/mL of the polymeric nanoparticles.